ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
Welcome!
Media
Live Quote
 
 

ValiRx plc

ValiRx plc listed on AIM in October 2006.  ValiRx is creating a portfolio of innovative products through investment in specific development projects.  ValiRx actively manages projects within this portfolio as a trading company and is not an investment vehicle.

The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints.  This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.